FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:961-963 March 1, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schrier, R. W. PubMed Citation

To the Editor: Schrier and colleagues (Nov. 16 issue)¹ report the overall efficacy and safety of tolvaptan in raising and maintaining serum sodium concentrations in patients with hyponatremia due to various causes. However, they do not report whether the primary end points were achieved in each of the subgroups (patients with the syndrome of inappropriate antidiuretic hormone secretion [SIADH], those with liver cirrhosis, and those with chronic heart failure), although a previous preliminary report suggests that this treatment results in differences in the resolution of hyponatremia among these groups.² Furthermore, little mention is made about whether the treatment groups were . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.